2-(4-((6-bromo-3-nitroquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile
CAS : 915019-51-1
Ref. 3D-QLB01951
1g | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté | ||
500mg | Arrêté |
Informations sur le produit
2-(4-((6-Bromo-3-nitroquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile (BIBFQ) is an irreversible inhibitor of tyrosine kinases. It is a psoriasis treatment that works by binding to the active site of the enzyme and preventing its activation. BIBFQ is also being studied as a possible treatment for restenosis, atherosclerosis, and endometriosis. The drug has shown some anti-cancer properties in vitro.